All In Biotech

Drug Trial Radar · NCT03222843

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura

Last checked: Nov 19, 2026Latest source record: Aug 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 424 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

424

Actual

Start

Jun 30, 2017

Primary completion

Nov 11, 2019

Study completion Jan 7, 2021

Sponsor

Sponsor type
Industry
First posted
Jul 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5\~.75 mg/day) to maintain platelet counts 50\~250×109/L

Conditions

  • Idiopathic Thrombocytopenic Purpura

Interventions

  • Hetrombopag OlamineDrug

    once daily

  • matching placeboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the proportion of patients with a platelet count ≥50×109/L after Day 57.Time frame: Baseline to Week 8

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Union Hospital Tongji Medical College Huazhong University of Science and technology

    Wuhan, Hubei, China

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China

  • Hospital of Blood Diseases, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.